Exicure: Developing nucleic acid therapeutics based on proprietary Spherical Nucleic Acid (SNA) technology. Cavrotolimod (AST-008) in Ph2 trials for patients with Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, with Ph1b data presented at AACR 2020. XCUR-FXN in preclinical development for patients with Friedreich's Ataxia, using genetically targeted SNA therapies to remove FXN transcription blockage, with IND expected in late 2020. Platform also applicable in derm, partnership with Allergan in hair loss disorders.
Based in...
US - East North Central
Public, USA
Market Cap
100MM - 500MM
8045 Lamon Ave.
Suite 410
Skokie, IL 60077
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Exicure, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Tybourne Capital Management (HK) Ltd. 9.66 7,340,000 15.05 13F 6/30/20
Abingworth LLP 9.18 6,977,000 14.30 13F 6/30/20
AWM Investment Co., Inc. 5.32 4,042,200 8.29 13F 6/30/20
The Vanguard Group, Inc. 3.79 2,882,496 5.91 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 3.77 2,864,927 5.87 13F 6/30/20
BlackRock Fund Advisors 2.70 2,054,124 4.21 13F 6/30/20
Sphera Funds Management Ltd. 2.50 1,900,000 3.90 13F 6/30/20
Ecor1 Capital LLC 2.20 1,673,301 3.43 13F 6/30/20
Northwestern University 2.06 1,564,372 3.21 13F 6/30/20
Knoll Capital Management LP 1.68 1,277,777 2.62 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.